Tin-Yun Tang, MD

Peer-Reviewed Articles

1. Ngoi NY, Tang TY, Gaspar CF, Pavlick DC, Buchold GM, Scholefield EL, Parimi V, Huang RS, Janovitz T, Danziger N, Levy MA, Pant S, De Armas AD, Kumpula D, Ross JS, Javle M, Ahnert JR. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers. Oncol, 2024. e-Pub 2024. PMID: 38330461.
2. Tang TY, Nichetti F, Kaplan B, Lonardi S, Pietrantonio F, Salvatore L, Vivaldi C, Rimassa L, de Braud F, Rizzato MD, Pavlick D, Chu R, Danner De Armas A, Sharaf A, Sokol E, Rodon Ahnert J, Ross JS, Javle M, Niger M. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clin Cancer Res, 2023. e-Pub 2023. PMID: 37773629.
3. Huang LF, Hong A, Cioffi G, Alahmadi A, Tang TY, Ocuin LM, Patil N, Bajor DL, Saltzman JN, Mohamed A, Selfridge E, Webb Hooper M, Barnholtz-Sloan J, Lee RT. Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After Surgery. Front Oncol 12, 2022. e-Pub 2022. PMID: 35273909.
4. Opneja A, Cioffi G, Alahmadi A, Jones N, Tang TY, Patil N, Bajor DL, Saltzman JN, Mohamed A, Selfridge E, Mangal A, Barnholtz-Sloan J, Lee RT. Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014. Cancer Med, 2021. e-Pub 2021. PMID: 34060249.
5. Ramachandran S, Coffin SL, Tang TY, Jobaliya CD, Spengler RM, Davidson BL. Cis-acting single nucleotide polymorphisms alter MicroRNA-mediated regulation of human brain-expressed transcripts. Hum Mol Genet 25(22):4939-4950, 2016. e-Pub 2016. PMID: 28171541.

Other Articles

1. Tang TY, Cruz VB, Konczal LL Idiopathic chronic pancreatitis treated with ivacaftor in a CFTR carrier with methylmalonic acidemia. J Cyst Fibros 21(4):603-605, 2022. PMID: 34974990.
2. Tang TY, Daunov K, Lee RT Case Report: Durable Response to Very Low Dose Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma. Front Oncol 11 - 2021, 2021. PMID: 34976819.

Abstracts

1. Tang TY, Danner De Armas A, Ross JS, Pavlick D, Sharaf R, Kaplan BG, Sokol E, Rodon Ahnert J, Javle M. Landscape of BRAF mutation classes in intrahepatic cholangiocarcinoma. J Clin Oncol 41(no. 4_suppl):599-599, 2023. e-Pub 2023.
2. Tang TY, Ross JS, Javle M. 63P Intrahepatic cholangiocarcinoma (iCCA) genomic findings with high versus low tumor mutational burdens. Ann Oncol 33(Supplement 7), 2022. e-Pub 2022.
3. Tang TY, Ross JS, Rodon Ahnert J, Javle M. Genomic profile of intrahepatic cholangiocarcinoma with MTAP loss. J Clin Oncol 40(16 Suppl):4102-4102, 2022. e-Pub 2022.
4. Tang TY, Stearns D, Miron A, Mitchell A. Pathogenic TP53 variant allele frequency across different somatic tissues in two patients with mosaic Li-Fraumeni. J Clin Oncol 40(16 suppl):10582-10582, 2022. e-Pub 2022.